Vaccines are the most effective and cost-effective way to protect billions of people worldwide, with vaccine development potentially transforming health by removing the burden of life-threatening infectious diseases from the population. India's capabilities in the manufacturing of vaccines came to the fore during the COVID-19 pandemic, where companies such as Bharat Biotech International Limited, were able to provide vaccines that met over 60% of the world's demand and supplied over 2.4 billion doses of COVID-19 vaccines. India continue to make significant R&D investments to develop a roadmap for the design and delivery of vaccine development for a future pandemic.
This MoU signifies a meaningful step towards advancing global health and driving vaccine innovation. Bharat Biotech International Limited and the University of Sydney are eager to embark on this collaborative journey, contributing to a healthier and more secure future for all.
Professor Jamie Triccas, Deputy Director at Sydney ID, emphasised the significance of this collaboration, saying, "Positioning Sydney ID on a global scale to drive innovation and highlight our expertise in the development of new vaccines and biotherapeutics is paramount. Together with Bharat Biotech International Limited, we aim to make a lasting impact on global health."
The reputational and societal impacts of developing novel vaccines to eradicate human and animal diseases that are safe, affordable, and effective cannot be overstated.
Dr. Krishna Ella, Executive Chairman said, "Mutually, we are excited about the new opportunities to strengthen our shared vision, leverage prowess of education, research capabilities to help build a healthier universe and improve people’s lives by developing safer vaccine platforms. Most importantly, build a talent of young scientists with a passion to innovate.”
This agreement reflects our ethos to facilitate collaborative research, foster innovation, and further advance the science vaccine technology.